Using model of hemorrhagic stroke in rats (heparinized autologous blood was injected into the subarachnoid space at a dose of 0.1 ml/100 g), we discovered that 21 days course of intravenous therapy with 1% solution of 1-adamantiloxy- 3-morpholino-2-propanolhydrochloride (ademol) at a dose of 2 mg/kg was more effective to reduce neurological deficit (from severe to moderate by stroke-index, p<0.05) and improve mnemotropic activity in the test of passive avoidance compared to nimodipine at a dose of 30 mg/kg. These findings proved neuroprotective properties of ademol. Therapy with ademol as well as with reference drug in the acute phase of subarachnoid hemorrhage (4th day) resulted in a decrease in the number of cells with fragmented DNA in the visual cortex in rats. The results of our study indicated anti-apoptotic action of ademol on the cortical neurons after hemorrhagic stroke. Taking into account pronounced mnemotropic and anti-apoptotic effects of ademol, it has been classified as a primary neuroprotective drug and can be used as pathogenetic therapeutic agent to prevent early cell death after stroke in human.